Subjects: Government Regulation and Prescription Fees - Digital Collections - National Library of Medicine Search Results

Start Over Subjects Government Regulation ✖ Subjects Prescription Fees ✖

1. CMS should bolster its oversight of manufacturer-submitted average sales price data to ensure accurate Part B drug payments

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022
Subject(s):: Cost Control
Drug Costs
Drug Industry
Government Regulation
Medicare Part B
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)

2. Manufacturers may need additional guidance to ensure consistent calculations of average sales prices

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, December 2022
Subject(s):: Drug Costs
Drug Industry
Government Regulation
Medicaid
Medicare Part B
Prescription Fees
United States

3. Medicare Part B drug payments: impact of price substitutions based on 2021 average sales prices

Publication:: Washington, D.C. : U.S. Department of Health and Human Services, Office of Inspector General, August 2023
Subject(s):: Cost Control
Drug Costs
Government Regulation
Medicare Part B
Prescription Fees
United States

4. Medicare Part D: CMS should monitor effects of rebates on plan formularies and beneficiary spending : report to congressional requesters

Publication:: Washington, DC : United States Government Accountability Office, September 2023
Subject(s):: Drug Costs
Government Regulation
Legislation, Medical
Medicare Part D -- economics
Medicare Part D -- organization & administration
Prescription Fees
United States
Centers for Medicare & Medicaid Services (U.S.)